Drug Approval | July 13, 2025
Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
mRNA-1010 demonstrated superior relative vaccine efficacy
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
No safety signals related to the vaccine candidate were identified
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
This is recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek’s disease
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Subscribe To Our Newsletter & Stay Updated
